Preservation of ovarian function with goserelin in young breast cancer patients: Does it hamper the effect of neoadjuvant chemotherapy?

被引：0
|
作者：
Wang, S. Y. [1 ]
Wang, S. [1 ]
机构：
[1] Peking Univ, Breast Surg, Peoples Hosp, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.045
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
107P
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant chemotherapy in young breast cancer patients:: Correlation between response and relapse?
    Braud, AC
    Asselain, B
    Scholl, S
    De la Rochefordière, A
    Palangie, T
    Dieras, V
    Pierga, JY
    Dorval, T
    Jouve, M
    Beuzeboc, P
    Pouillart, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) : 392 - 397
  • [32] CHEMORESISTANCE TO NEOADJUVANT CHEMOTHERAPY IN YOUNG PATIENTS WITH ER-POSITIVE BREAST CANCER
    Moon, B.
    Seoh, J.
    Woo, J.
    Lim, W.
    ANNALS OF ONCOLOGY, 2014, 25
  • [33] Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy.
    Delrieu, Lidia
    Hamy, Anne-Sophie
    Coussy, Florence
    Kassara, Amyn
    Asselain, Bernard
    Antero, Juliana
    De Villele, Paul
    Dumas, Elise
    Forstmann, Nicolas
    Guerin, Julien
    Hotton, Judicael
    Jouannaud, Christelle
    Milder, Maud
    Leopold, Armand
    Sedeaud, Adrien
    Soibinet, Pauline
    Toussaint, Jean-Francois
    Vercamer, Vincent
    Laas, Enora
    Reyal, Fabien
    CANCER RESEARCH, 2022, 82 (12)
  • [34] Does neoadjuvant chemotherapy regimen affect sarcopenia status in patients with breast cancer?
    Jang, Min Kyeong
    Park, Seho
    Park, Chang
    Doorenbos, Ardith Z.
    Go, Jieon
    Kim, Sue
    BREAST, 2022, 66 : 1 - 7
  • [35] Protection of ovarian function with an LH-RH analogue during chemotherapy in young breast cancer patients
    Ogawa, M.
    Masuda, N.
    Yamamura, J.
    Masuda, H.
    Karita, M.
    Nakamori, S.
    Tsujinaka, T.
    BREAST, 2009, 18 : S66 - S67
  • [36] Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
    Le, T.
    Latifah, H.
    Jolicoeur, L.
    Weberpals, J.
    Faught, W.
    Hopkins, L.
    Fung, M. Fung Kee
    GYNECOLOGIC ONCOLOGY, 2011, 121 (03) : 451 - 454
  • [37] Does the Diagnosis Center Influence the Prognosis of Ovarian Cancer Patients Submitted to Neoadjuvant Chemotherapy?
    Vizzielli, Giuseppe
    Fanfani, Francesco
    Chiantera, Vito
    Tortorella, Lucia
    Lucidi, Alessandro
    Petrillo, Marco
    Costantini, Barbara
    Scambia, Giovanni
    Fagotti, Anna
    ANTICANCER RESEARCH, 2015, 35 (05) : 3027 - 3032
  • [38] The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer
    Leonard, R. C.
    Adamson, D.
    Anderson, R.
    Ballinger, R.
    Bertelli, G.
    Coleman, R. E.
    Fallowfield, L.
    McLinden, M.
    Mansi, J.
    Thomas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Does fertility preservation affect the start of the oncological treatment and the response to neoadjuvant chemotherapy in breast cancer.
    Baulies, Sonia
    Izquierdo, Maxim
    Devesa, Marta
    Rodriguez, Ignacio
    Tresserra, Fransec
    Fabregas, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Ovarian function preservation in patients under chemotherapy treatment
    Tempone, Antonio
    GYNECOLOGICAL ENDOCRINOLOGY, 2008, 24 (09) : 481 - 482
12345